Mylan plans to merge with a spinoff from Pfizer, and Merck had more good news about its blockbuster cancer drug.
News & Analysis: Mylan
The drugmaker's revenue improved in the second quarter with new product launches, but higher spending weighed on its earnings.
A proposed combination with Pfizer's Upjohn unit is exciting Mylan shareholders.
Stocks were mixed on Wall Street Monday morning.
The pharmaceutical giant will reportedly combine its legacy products business with generic drug major Mylan.
The industry drew the ire of 44 state attorneys general alleging widespread conspiracy to inflate drug prices.
Forty-four states have brought a lawsuit against the industry.
MYL earnings call for the period ending March 31, 2019.
The drugmaker's challenges in the U.S. generics market and problems at a manufacturing facility weighed on its first-quarter revenue and earnings.
The drugmaker's Q1 update is weighing on its share price.